Longer tamoxifen use reduces breast cancer recurrence (Reuters, 2 June 2013)

03 Jun 2013


A UK study presented at the annual American Society of Clinical Oncology meeting, part of a larger international trial, assesses the risk-benefit balance of using tamoxifen for five versus ten years in the treatment of breast cancer.

Full article


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story